Clinical Trials
For more information about clinical trials, please refer to the National Institutes of Health (NIH) overview of the clinical trial process, available at www.clinicaltrials.gov or by clicking on the Protocol ID and NCI Study below.
| Cloretazine® (VNP40101M) |
| Protocol ID |
Title |
Sites |
|
Phase II Study of Cloretazine® (VNP40101M) for Elderly Patients with de novo Poor Risk Acute Myelogeous Leukemia
|
3 Sites open
in North America
|
|
Dose Escalation Trial of Cloretazine® (VNP40101M) and Hematopoietic Cell Transplantation for Patients with Selected, Poor-Prognosis Hematologic Malignancies
|
|
|
A Phase I/II Trial of Cloretazine® (VNP40101M) and Temodar® (Temozolomide) for Patients with Malignant Gliomas in 1st Relapse or Progression
|
|
* Investigator initiated trial
|
Triapine®
Sponsored by the National Institute of Health (NIH) |
| NCI Study |
Title |
Sites |
|
Phase II Study of Triapine® in Combination with Gemcitabine in Adenocarcinoma of the Biliary Ducts and Gall Bladder
|
|
|
A Phase I Study of a Prolonged Infusion of Triapine in Combination with a Fixed Dose Rate of Gemcitabine in Patients with Advanced Solid Tumors and Lymphomas
|
|
|
A Phase I Study of Triapine® in Combination with Radiation Therapy in Locally Advanced Pancreas Cancer
|
|
|
A Phase I and Pharmacokinetic Study of Oral Triapine® in the Treatment of Advanced Solid Tumors |
|
|
Phase I Study of Intravenous Triapine® in Combination with Pelvic Radiation Therapy with or without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies |
|
|
Phase II Study of Triapine® and Plus Fludarabine in Treating Patients With Myeloproliferative Disorders, Including Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia |
|
We hope we have provided you with answers to some of your questions. If you have a specific question please contact us. |
